Creabilis appoints new chief executive

Eliot Forster brings significant drug development experience to firm

Creabilis, a clinical stage European biotechnology company addressing significant unmet medical needs in dermatological diseases, has appointed Eliot Forster as its new chief executive.

Forster brings almost 20 years’ industry experience in biotechnology and pharmaceutical companies to the Luxembourg-based firm.

He was most recently chief executive of Solace Pharmaceuticals, a US-based biotech. Prior to this, was Pfizer’s head of EU development and of development operations in the EU and Asia. During his career at Pfizer Forster was integral to bringing a number of drugs to market, including Celebrex (celecoxib), Bextra (valcecoxib) and Relpax (eletriptan).

Creabilis’ lead product is CT327, a novel topically applied TrkA kinase inhibitor developed using the Company’s LSE (Low Systemic Exposure) technology. It is currently in Phase II clinical trials in psoriasis and atopic dermatitis.

The Creabilis portfolio also includes CT637, a new approach to the treatment of significant inflammatory conditions such as rheumatoid arthritis as well as severe psoriasis.

You may also like

Finance

Creabilis establishes UK operation

Location in Kent broadens the county’s links with the pharma industry
Research & Development

Cirena and Epigenica launch technologies to accelerate genome editing and epigenomic research

Two life sciences companies have announced new technologies designed to address long-standing bottlenecks in genome editing and epigenomic analysis, offering faster timelines and improved reproducibility for researchers in academia and industry
Research & Development

PSI launches platform to speed up site ID, startup and enrolment in pivotal studies

SYNETIC is designed to speed up site identification, startup and patient enrollment in pivotal clinical trials
Ingredients

Piramal Pharma Solutions introduces tablet-in-capsule capabilities

Enhancing dosing flexibility and patient-centric drug delivery
Pharmaceutical

PharmNovo enhances its board ahead of Phase II development

The new board members bring complementary experience in drug development, clinical execution and partnering, supporting the company’s continued progress and dialogue with potential partners
Research & Development

AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic

The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies
Research & Development

Baseline Therapuetics launches to advance GLP-1 Phase III Programme in Alcohol Use Disorder

The clinical-stage biotech has launched to progress BT-001, a once-weekly GLP-1 receptor agonist, into FDA-aligned Phase III trials for alcohol use disorder, with studies planned to begin in 2026
Subscribe now